Evidence map›Paper›PMID 25109334›Full record

ArticleOncogene2015

Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.

A Agarwal, R J MacKenzie, C A Eide, M A Davare, K Watanabe-Smith, C E Tognon, S Mongoue-Tchokote, B Park, R M Braziel, J W Tyner and 1 more

Open access · greenAbstract read
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. How Genomic and Structural Context Could Shape JAK-STAT Variant Pathogenicity.Twin research and human genetics : the official journal of the International Society for Twin Studies · 2026
    Article
  2. Article
  3. Review
  4. In vivo impact of JAK3 A573V mutation revealed using zebrafish.Cellular and molecular life sciences : CMLS · 2022
    Article
  5. Article
  6. Identification of U937Frontiers in oncology · 2021
    Article
  7. Article
  8. Article
  9. RNAi Screening of Leukemia Cells Using Electroporation.Methods in molecular biology (Clifton, N.J.) · 2016
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

A Agarwal1] Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USA [2] Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
R J MacKenzie1] Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USA [2] Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
C A Eide1] Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USA [2] Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA [3] Howard Hughes Medical Institute, Portland, OR, USA.
M A DavareDepartment of Pediatrics, Oregon Health & Science University, Portland, OR, USA.
K Watanabe-Smith1] Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USA [2] Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
C E Tognon1] Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA [2] Howard Hughes Medical Institute, Portland, OR, USA.
S Mongoue-Tchokote1] Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA [2] Biostatistics Shared Resource, Oregon Health & Science University, Portland, OR, USA.
B Park1] Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA [2] Biostatistics Shared Resource, Oregon Health & Science University, Portland, OR, USA.
R M BrazielDepartment of Pathology, Oregon Health & Science University, Portland, OR, USA.
J W Tyner1] Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA [2] Department of Cell & Developmental Biology, Oregon Health & Science University, Portland, OR, USA.
B J Druker1] Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USA [2] Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA [3] Howard Hughes Medical Institute, Portland, OR, USA.
Oregon Health & Science University · US

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Program in Molecular and Cellular BiosciencesT32GM071338 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI MASLEN, CHERYL L · 2005 to 2020
$3.5M
Role of p27 in chronic myeloid leukemia and its potential as a therapeutic targetR00CA151670 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI AGARWAL, ANUPRIYA · 2014 to 2016
$738k
ROR1 as a Therapeutic Target in Acute Lymphoblastic LeukemiaR00CA151457 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI TYNER, JEFFREY WALLACE · 2012 to 2014
$723k
Role of p27 in chronic myeloid leukemia and its potential as a therapeutic targetK99CA151670 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI AGARWAL, ANUPRIYA · 2011 to 2012
$283k
Howard Hughes Medical InstituteNCI NIH HHS 1R01CA183947-01NCI NIH HHS (5 K99 CA151670-02NCI NIH HHS 5R00CA151457-04NCI NIH HHS K99 CA151670NCI NIH HHS P30 CA069533NCI NIH HHS R00 CA151457NCI NIH HHS R00 CA151670NIGMS NIH HHS T32 GM071338
6 · The paper itself

Abstract

To understand the role of cytokine and growth factor receptor-mediated signaling in leukemia pathogenesis, we designed a functional RNA interference (RNAi) screen targeting 188 cytokine and growth factor receptors that we found highly expressed in primary leukemia specimens. Using this screen, we identified interleukin-2 gamma receptor (IL2Rγ) as a critical growth determinant for a JAK3(A572V) mutation-positive acute myeloid leukemia cell line. We observed that knockdown of IL2Rγ abrogates phosphorylation of JAK3 and downstream signaling molecules, JAK1, STAT5, MAPK and pS6 ribosomal protein. Overexpression of IL2Rγ in murine cells increased the transforming potential of activating JAK3 mutations, whereas absence of IL2Rγ completely abrogated the clonogenic potential of JAK3(A572V), as well as the transforming potential of additional JAK3-activating mutations such as JAK3(M511I). In addition, mutation at the IL2Rγ interaction site in the FERM domain of JAK3 (Y100C) completely abrogated JAK3-mediated leukemic transformation. Mechanistically, we found IL2Rγ contributes to constitutive JAK3 mutant signaling by increasing JAK3 expression and phosphorylation. Conversely, we found that mutant, but not wild-type JAK3, increased the expression of IL2Rγ, indicating IL2Rγ and JAK3 contribute to constitutive JAK/STAT signaling through their reciprocal regulation. Overall, we demonstrate a novel role for IL2Rγ in potentiating oncogenesis in the setting of JAK3-mutation-positive leukemia. In addition, our study highlights an RNAi-based functional assay that can be used to facilitate the identification of non-kinase cytokine and growth factor receptor targets for inhibiting leukemic cell growth.

Indexed as

AnimalsBinding SitesCell Line, TumorCell Transformation, NeoplasticHumansInterleukin Receptor Common gamma SubunitJanus Kinase 3LeukemiaMiceMolecular Sequence DataMutationPhosphorylationRNA, Small InterferingSignal TransductionIL2RG protein, humanIl2rg protein, mouseInterleukin Receptor Common gamma SubunitJAK3 protein, humanJanus Kinase 3RNA, Small Interfering

Identifiers

PMID25109334
PMCPMC4324389
OpenAlexW1978505760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.